Response rates after 1 year of treatment with anti-TNF agents. Except where indicated otherwise, values are percentages.
| n | Private Practices | Academic Centers | OR (95% CI) | p | |
|---|---|---|---|---|---|
| All Patients with Axial SpA | |||||
| ASAS40 | 336 | 48.5 | 43.4 | 1.22 (0.71–2.13) | 0.51 |
| ASDAS clinically important improvement | 296 | 59.7 | 60.0 | 0.99 (0.55–1.77) | 1.00 |
| ASDAS major improvement | 296 | 35.8 | 32.9 | 1.14 (0.63–2.12) | 0.67 |
| ASDAS inactive disease | 296 | 16.9 | 20.0 | 0.81 (0.40–1.74) | 0.59 |
| Patients with AS | |||||
| ASAS40 | 231 | 51.7 | 52.9 | 0.95 (0.48–1.86) | 1.00 |
| Patients with Nonradiographic Axial | |||||
| SpA ASAS40 | 60 | 27.5 | 25.0 | 1.14 (0.29–4.97) | 1.00 |
Anti-TNF: anti-tumor necrosis factor; SpA: spondyloarthritis; ASAS: Assessment of SpondyloArthritis international Society; ASAS40: ≥ 40% improvement according to ASAS; ASDAS: Ankylosing Spondylitis Disease Activity Score.